Multisystem inflammatory syndrome in children — Initial therapy and outcomes
New England Journal of Medicine — Son MBF, Murray N, Friedman K, et al. | June 18, 2021
Researchers aimed at assessing the real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C). Surveillance data on inpatients younger than 21 years of age who had MIS-C who were admitted to 1 of 58 US hospitals, were analyzed. They identified 518 patients with MIS-C (median age, 8.7 years) who underwent at least one immunomodulatory therapy; 75% of these had been previously healthy, and 9 died. Among these inpatients, a lower risk of new or persistent cardiovascular dysfunction was observed in correlation with receiving initial treatment with IVIG plus glucocorticoids vs IVIG alone.